Hyperparathyroidism Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.PTH Attenuation Trial in Hemodialysis-2
Conditions: Secondary Hyperparathyroidism; End Stage Kidney Disease Interventions: Drug: PLS240; Drug: Placebo; Drug: Open-Label Extension PLS240 Sponsors: Pathalys Pharma; Launch Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2023 Category: Research Source Type: clinical trials
PTH Attenuation Trial in Hemodialysis-1
Condition: Secondary Hyperparathyroidism Interventions: Drug: PLS240; Drug: Placebo; Drug: Open-Label Extension PLS240 Sponsors: Pathalys Pharma; Launch Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
